1. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations
   Nilsa Rivera-Del Valle et al, 2018, Cancer Chemother Pharmacol CrossRef
2. Discovery of the First-in-Class Dual Histone Deacetylase–Proteasome Inhibitor
   Sanil Bhatia et al, 2018, J. Med. Chem. CrossRef
3. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
   Yu Bai et al, 2019, Curr Top Med Chem CrossRef
4. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells
   Yi-Yen Yeh et al, 2017, Invest New Drugs CrossRef
5. Role of HDACs in normal and malignant hematopoiesis
   Pan Wang et al, 2020, Mol Cancer CrossRef
6. The FKH domain in FOXP3 mRNA frequently contains mutations in hepatocellular carcinoma that influence the subcellular localization and functions of FOXP3
   Jianwei Ren et al, 2020, J. Biol. Chem. CrossRef
7. Oxidative stress response induced by chemotherapy in leukemia treatment (Review)
   Jin Zhang et al, 2018, mol clin onc CrossRef